MarketPulse
M

$MOLN

5 articles found
4 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Molecular Partners to Showcase Experimental Cancer Therapy MP0712 at Major 2026 Conferences

Molecular Partners will present its DLL3-targeting Radio-DARPin candidate MP0712 at three major scientific conferences in May 2026, highlighting early clinical trial data.
MOLNclinical developmentsmall cell lung cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Molecular Partners Ag

Molecular Partners' MP0317 Shows Promise in Nature Cancer, Sparks CD40 Agonist Competition

Molecular Partners published positive Phase 1 data for MP0317, a CD40 agonist, in Nature Cancer, demonstrating tumor microenvironment remodeling with favorable safety in advanced cancer patients.
MOLNPhase 1 clinical trialimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Molecular Partners Wins Shareholder Approval, Adds Pharma Veteran Clare Fisher to Board

Molecular Partners shareholders approved all board proposals and elected pharma veteran Clare Fisher as director. The company reported CHF 57.9M loss in 2025 with CHF 257.3M accumulated deficit.
MOLNfinancial resultsclinical-stage biotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Molecular Partners Taps Healthcare M&A Veteran Clare Fisher for Board Seat

Molecular Partners nominates M&A veteran Clare Fisher to its board as 12-year member Steven Holtzman retires, signaling strategic emphasis on business development and partnerships.
MOLNONCbiotechAnnual General Meeting
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Molecular Partners Posts $61.7M Loss but Funds Pipeline Through 2028

Molecular Partners reports CHF 61.7M net loss but maintains CHF 93.1M cash runway through 2028, advancing Radio-DARPin and immuno-oncology pipeline programs.
MOLNfinancial resultsclinical trial